#gene therapy #Genprex #GNPX

Genprex Announces Registered Direct Offering of up to $10 Million

Genprex, Inc., a clinical-stage gene therapy company, has disclosed its plans for a registered direct offering valued at up to $10 million, which will be conducted in accordance with Nasdaq regulations. The company seeks to generate funds for continuing its exploration and development of revolutionary therapies targeting cancer and diabetes, areas where patients often find limited treatment options.

Details of the Offering

The offering consists of 377,780 shares being sold at a set price of $9.00 each. In addition, Genprex will also be offering short-term warrants that may allow investors to purchase up to 755,560 additional shares at $8.75 each. Immediate exercise of these warrants is permitted, with a two-year expiration time frame once the mandatory registration statement is effective. Expected to close by October 29, 2025, this offering has generated attention due to its potential value for investors and its implications for the company's operational funding.

H.C. Wainwright & Co. has been appointed as the sole placement agent for this offering, managing the placement of securities in alignment with market standards.

Financial Implications

The anticipated gross proceeds from this transaction will amount to approximately $3.4 million before any deductions related to placement agent fees or other associated offerings expenses. Furthermore, if investors exercise the short-term warrants fully, additional gross proceeds could reach approximately $6.6 million. However, no assurances are provided that these warrants will be exercised. Proceeds from this offering are designated for operational and corporate expenses, demonstrating Genprex's strategic approach to funding its ongoing projects.

Understanding Genprex and Its Mission

Genprex is committed to developing innovative gene therapies for patients suffering from severe conditions, particularly focusing on cancer and diabetes. The company's flagship product, Reqorsa® Gene Therapy, is currently undergoing clinical trials for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), both of which have been given Fast Track Designation by the FDA. This reflects a recognized urgency in providing new therapies to patients.

In addition to its cancer-focused treatments, Genprex is advancing its gene therapy approach for diabetes, leveraging innovative methods to transform pancreatic cells into functional insulin-producing entities. Such advancements demonstrate Genprex's dedication to redefining treatment paradigms for debilitating diseases.

Regulatory and Market Considerations

Notably, the shares offered in this registered direct offering are subject to a